

CONTROVERSIES & UPDATES IN VASCULAR SURGERY

JANUARY 23-25 2020 4

Peripheral VA-ECMO: open or percutaneous approach?

P Mordant, Q Pellenc, A Roussel, P Cerceau, Y Castier Service de chirurgie vasculaire, thoracique, et de transplantation pulmonaire Hôpital Bichat, Assistance Publique – Hôpitaux de Paris Unité INSERM 1152, Université de Paris pierre.mordant@aphp.fr



MARRIOTT RIVE GAUCHE & CONFERENCE CENTER | PARIS | FRANCE
WWW.CACVS.ORG

Disclosure

Speaker name:

Pierre Mordant

I have the following potential conflicts of interest to report:

Consulting

Employment in industry

Shareholder in a healthcare company

Owner of a healthcare company

X Other(s): 3 patents related to arterial ECMO canula (w/ APHP)

I do not have any potential conflict of interest




CONTROVERSIES & UPDATES IN VASCULAR SURGERY



JANUARY 23-25 2020

MARRIOTT RIVE GAUCHE & CONFERENCE CENTER | PARIS | FRANCE WWW.CACVS.ORG


- ECMO is effective in various circumstances
 - Cardiogenic shock
 - Refractory cardiac arrest
 - Right heart failure 2nd pulmonary disease
 - Intraoperative support of lung transplantation
- The number of VA-ECMO is increasing
 - x 5 between 2012 and 2014 in Germany
 - 3.5/100.000/year
 - 2766 ECMOs in 2016 in France
 - 4.1/100.000/year
 - Out-of-hospital cardiac arrest?
 - 61/100.000/year...







MARRIOTT RIVE GAUCHE & CONFERENCE CENTER | PARIS | FRANCE WWW.CACVS.ORG





• The use of peripheral VA-ECMO is still associated with peripheral complications (meta-analysis, n=1866)

• Limb ischemia 16.9%

• Fasciotomy 10.3%

• Amputation 4.7%

• Infection 30.4%

• Local infections are inconstantly reported (series, n=899)

• Canulation site 22.3%


• Requiring revision 9.9%





MARRIOTT RIVE GAUCHE & CONFERENCE CENTER | PARIS | FRANCE WWW.CACVS.ORG

Pitié Experience, 2014-2016, n=899 VA ECMO
Technique of percutaneous insertion – percutaneous decanulation using Femostop®





CONTROVERSIES & UPDATES IN VASCULAR SURGERY



JANUARY 23-25 2020

MARRIOTT RIVE GAUCHE & CONFERENCE CENTER | PARIS | FRANCE WWW.CACVS.ORG

Pitié Experience, 2014-2016, n=899 VA ECMO

matching 266 surgical / 266 percutaneous insertion – percutaneous decanulation using Femostop®

	Surgical group $n = 266 (\%)$	Percutaneous group n = 266 (%)	<i>p</i> value	
30-Day overall survival	150 (56.3)	170 (63.8)	0.034	
Cannulation site infection	74 (27.8)	44 (16.5)	0.001	Less groin
Infection requiring surgical revisiona	40 (15.0)	14 (5.3)	< 0.001	infections
Vascular complications at cannulation ^b	7 (2.6)	10 (3.8)	0.663	_
Limb ischemia	33 (12.4)	23 (8.6)	0.347	Comparable
Cannula relocation or removal	25 (9.4)	15 (5.6)	0.258	limb
Limb fasciotomy	10 (3.8)	6 (2.3)	0.310	ischemia
Amputation	2 (0.8)	2 (0.8)	1.000	
Vascular complications after cannula removal	9 (3.4)	39 (14.7)	< 0.001	More
Surgical revision for persistent bleeding early after decannulation	4 (1.5)	25 (9.4)	< 0.001	revisions for
Surgical revision in the days after decannulation ^c	5 (1.9)	14 (5.3)	0.035	bleeding
Lower limb sensory-motor deficit	6 (2.3)	7 (2.6)	0.779	_



CONTROVERSIES & UPDATES IN VASCULAR SURGERY



JANUARY 23-25 2020

MARRIOTT RIVE GAUCHE & CONFERENCE CENTER | PARIS | FRANCE WWW.CACVS.ORG

Pitié Experience, 2014-2016, n=899 VA ECMO matching 266 surgical / 266 percutaneous insertion – percutaneous decanulation using Femostop®

Variables	Univariable analysis		Multivariable analysis	Multivariable analysis	
	OR (95% CI)	p value	OR (95% CI)	p value	
Percutaneous approach	0.46 (0.32–0.66)	< 0.001	0.40 [0.27–0.59]	< 0.001	
Chronic heart failure	1.86 (1.33-2.62)	< 0.001	1.55 [1.08-2.23]	0.018	
Duration of VA-ECMO		< 0.001		< 0.001	
< 3 days	1		1		
≥ 3 and < 6 days	4.92 (2.50-10.61)		4.25 (1.99–9.1)		
≥ 6 and < 10 days	8.92 (4.59-19.12)		8.14 (3.84-17.25)		
≥ 10 days	11.48 (5.95–24.46)		10.03 (4.77-21.10)		
Reperfusion	10.19 (2.17-181.78)	0.005	-	-	
SOFA score	0.95 (0.91-0.98)	0.003	-	NS	
VA-ECMO implanted under cardiopulmo- nary resuscitation	0.45 (0.27–0.78)	0.006	-	NS	




CONTROVERSIES & UPDATES IN VASCULAR SURGERY



JANUARY 23-25 2020

MARRIOTT RIVE GAUCHE & CONFERENCE CENTER | PARIS | FRANCE WWW.CACVS.ORG

Bichat experience, 2011-2017, n=154 VA ECMO for LT Technique of percutaneous insertion – percutaneous decanulation using Proglide®




Percutaneous insertion (15-19F) w/ reperfusion


ECMO support Median 1 day

Percutaneous decanulation


Closing of the femoral artery Proglide® device















MARRIOTT RIVE GAUCHE & CONFERENCE CENTER | PARIS | FRANCE WWW.CACVS.ORG

Bichat experience, 2011-2017, n=154 VA ECMO for LT Comparing 48 surgical / 106 percutaneous insertion – percutaneous decanulation using proglide®

	Surgical group n = 48	Percutaneous group n = 106	p-value	
All local infectious complications	19 (39%)	1 (0.9%)	< 0.001	
Groin healing delay	10 (20,8%)	1 (0.9%)	< 0.001	Less groin infections
Groin wound infection	9 (18,9%)	0 (0%)	< 0.001	
Acute limb ischemia	1 (2,1%)	2 (1.8%)	ns	
Fasciotomy	1 (2,1%)	1 (0.9%)	ns	Comparable limb ischemi
Major amputation	0 (0%)	1 (0.9%)	ns	Comparable
Revision for bleeding	3 (6.3%)	0	ns	revisions for
				bleeding



CONTROVERSIES & UPDATES IN VASCULAR SURGERY



JANUARY 23-25 2020

MARRIOTT RIVE GAUCHE & CONFERENCE CENTER | PARIS | FRANCE
WWW.CACVS.ORG

Limitations

- Retrospective single center
- Short duration of ECMO support
- Use of a vascular closing device
- Still vascular complications (11%)

	30,0%	Vascular	Vascular complication rate with growing experience			
	30,070	25.00/				
(%)	25,0%	25,0%				
tion rate	20,0%	-				
complica	15,0%				11,5%	
Vascular complication rate (%)	10,0%					
	5,0%		3,7%	3,8%		
	0,0%	First quarter (n=27)	Second quarter (n=27)	Third quarter (n=26)	Fourth quarter (n=26)	

Factors associated with limb ischemia

Variables	ariables Univariable analysis		Multivariable analysis	
	OR (95% CI)	p value	OR (95% CI)	p value
SOFA score	1.11 (1.06–1.17)	< 0.001	1.12 (1.06–1.18)	< 0.001
Peripheral artery disease	2.63 (0.94–6.32)	0.048	-	NS
Reperfusion	0.41 (0.18–1.06)	0.072	-	NS
Chronic heart failure	0.57 (0.35–0.92)	0.022	-	NS
Arterial cannula size	1.08 (0.88–1.29)	0.526	-	-
lpsilateral arterial/ controlateral venous cannula- tion	1.46 (0.88–2.38)	0.136	-	-
Percutaneous approach	0.83 (0.50–1.34)	0.446	-	-

Danial / Lebreton Intensive Care Med 2018

dwith	complications
>	atic
te	<u>::</u>
associated	np
SO	Ö
as	ar (
Factors	vascular
ij	3SC
ις.	Š

2	Variables	OR	CI 95	р
כם כ	Male sex	0.11	0.02-0.26	0.014
complications	Peripheral arterial disease	22.32	3.48-214.11	<0.001
	ECMO duration	1.61	1.10-2.47	0.018
ascalai	Early experience	2.68	0.59-12.36	0.190

Pellenc / Castier EJCTS in press




CONTROVERSIES & UPDATES IN VASCULAR SURGERY




JANUARY 23-25 2020


MARRIOTT RIVE GAUCHE & CONFERENCE CENTER | PARIS | FRANCE WWW.CACVS.ORG

- Perspectives
 - Better strategies are needed to preserve the blood flow of both superficial and profundis femoral arteries
 - Integrating a distal perfusion catheter in a dual-lumen canula might be a solution given that it can be used percutaneously



Livanova Bi-flow®





Xperf prototype



MARRIOTT RIVE GAUCHE & CONFERENCE CENTER | PARIS | FRANCE WWW.CACVS.ORG

- In VA ECMO, percutaneous canulation is associated with a decreased rate of infection and a comparable rate of limb ischemia as compared with open approach
- Post ECMO manual compression and Femostop® are associated with a 15% rate of revisions to stop bleeding
- Pre ECMO preclosing of the femoral artery and Proglide® are associated with a low rate of revisions to stop bleeding
- In our experience, preclosing of the femoral artery allows total percutaneous VA ECMO in the setting of lung transplantation
- This technique could be applied to other indications for VA-ECMO with the potential to eradicate local infections and surgical revisions for bleeding.
- Better prevention of limb ischemia during VA ECMO is still needed.